375 related articles for article (PubMed ID: 25455704)
1. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.
Heres S; Lambert M; Vauth R
Eur Psychiatry; 2014 Nov; 29 Suppl 2():1409-13. PubMed ID: 25455704
[TBL] [Abstract][Full Text] [Related]
2. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
Kane JM; McEvoy JP; Correll CU; Llorca PM
CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
4. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
Haddad PM; Taylor M; Niaz OS
Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
6. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
7. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
Graffino M; Montemagni C; Mingrone C; Rocca P
Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
[TBL] [Abstract][Full Text] [Related]
8. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
Correll CU; Lauriello J
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505193
[TBL] [Abstract][Full Text] [Related]
9. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
10. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
12. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.
Taylor M; Ng KY
Aust N Z J Psychiatry; 2013 Jul; 47(7):624-30. PubMed ID: 23209308
[TBL] [Abstract][Full Text] [Related]
13. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome.
Olagunju AT; Clark SR; Baune BT
Aust N Z J Psychiatry; 2019 Jun; 53(6):509-527. PubMed ID: 30957510
[TBL] [Abstract][Full Text] [Related]
14. Long-acting injectable antipsychotics: evidence of effectiveness and use.
Manchanda R; Chue P; Malla A; Tibbo P; Roy MA; Williams R; Iyer S; Lutgens D; Banks N
Can J Psychiatry; 2013 May; 58(5 Suppl 1):5S-13S. PubMed ID: 23945067
[TBL] [Abstract][Full Text] [Related]
15. Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.
Bera RB
J Clin Psychiatry; 2014; 75 Suppl 2():30-3. PubMed ID: 24919169
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
Stevens GL; Dawson G; Zummo J
Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
[TBL] [Abstract][Full Text] [Related]
18. Clinical guideline recommendations for antipsychotic long-acting injections.
Kane JM; Garcia-Ribera C
Br J Psychiatry Suppl; 2009 Nov; 52():S63-7. PubMed ID: 19880920
[TBL] [Abstract][Full Text] [Related]
19. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.
Suzuki T
Expert Opin Drug Deliv; 2016; 13(2):253-64. PubMed ID: 26636244
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
Lin CH; Chen FC; Chan HY; Hsu CC
Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
